image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 536.49
-0.256 %
$ 192 B
Market Cap
77.67
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ISRG stock under the worst case scenario is HIDDEN Compared to the current market price of 536 USD, Intuitive Surgical, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ISRG stock under the base case scenario is HIDDEN Compared to the current market price of 536 USD, Intuitive Surgical, Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ISRG stock under the best case scenario is HIDDEN Compared to the current market price of 536 USD, Intuitive Surgical, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ISRG

image
$620.0$620.0$600.0$600.0$580.0$580.0$560.0$560.0$540.0$540.0$520.0$520.0$500.0$500.0$480.0$480.0$460.0$460.0$440.0$440.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
8.35 B REVENUE
17.24%
2.35 B OPERATING INCOME
32.95%
2.34 B NET INCOME
28.62%
2.42 B OPERATING CASH FLOW
33.15%
-3.27 B INVESTING CASH FLOW
-808.86%
151 M FINANCING CASH FLOW
152.47%
2.25 B REVENUE
-6.63%
578 M OPERATING INCOME
-21.34%
704 M NET INCOME
2.28%
582 M OPERATING CASH FLOW
-29.30%
214 M INVESTING CASH FLOW
116.89%
-236 M FINANCING CASH FLOW
-477.33%
Balance Sheet Intuitive Surgical, Inc.
image
Current Assets 7.11 B
Cash & Short-Term Investments 4.01 B
Receivables 1.36 B
Other Current Assets 1.74 B
Non-Current Assets 11.6 B
Long-Term Investments 4.82 B
PP&E 4.65 B
Other Non-Current Assets 2.17 B
21.41 %7.24 %9.29 %25.71 %24.79 %11.56 %Total Assets$18.7b
Current Liabilities 1.75 B
Accounts Payable 193 M
Short-Term Debt 0
Other Current Liabilities 1.55 B
Non-Current Liabilities 468 M
Long-Term Debt 0
Other Non-Current Liabilities 468 M
8.74 %70.11 %21.16 %Total Liabilities$2.2b
EFFICIENCY
Earnings Waterfall Intuitive Surgical, Inc.
image
Revenue 8.35 B
Cost Of Revenue 2.72 B
Gross Profit 5.63 B
Operating Expenses 3.29 B
Operating Income 2.35 B
Other Expenses 11.4 M
Net Income 2.34 B
9b9b8b8b7b7b6b6b5b5b4b4b3b3b2b2b1b1b008b(3b)6b(3b)2b(11m)2bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
67.46% GROSS MARGIN
67.46%
28.12% OPERATING MARGIN
28.12%
27.81% NET MARGIN
27.81%
14.13% ROE
14.13%
12.39% ROA
12.39%
12.08% ROIC
12.08%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Intuitive Surgical, Inc.
image
2b2b2b2b1b1b1b1b1b1b800m800m600m600m400m400m200m200m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 2.34 B
Depreciation & Amortization 462 M
Capital Expenditures -1.11 B
Stock-Based Compensation 677 M
Change in Working Capital -919 M
Others 300 K
Free Cash Flow 1.3 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Intuitive Surgical, Inc.
image
Wall Street analysts predict an average 1-year price target for ISRG of $535 , with forecasts ranging from a low of $410 to a high of $650 .
ISRG Lowest Price Target Wall Street Target
410 USD -23.58%
ISRG Average Price Target Wall Street Target
535 USD -0.20%
ISRG Highest Price Target Wall Street Target
650 USD 21.16%
Price
Max Price Target
Min Price Target
Average Price Target
650650600600550550500500450450400400350350Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Intuitive Surgical, Inc.
image
Sold
0-3 MONTHS
30.1 M USD 10
3-6 MONTHS
7.78 M USD 6
6-9 MONTHS
42 M USD 9
9-12 MONTHS
20.2 M USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
The Transformative Rise of Global Robotics: A 2025 Market Analysis Robotics is poised for robust growth in 2025. Watch NVDA, ISRG, SERV and PATH for potential market dominance across healthcare, manufacturing and mobility sectors. zacks.com - 1 week ago
Stock Picks From Seeking Alpha's April 2025 New Analysts In April, Seeking Alpha welcomed 20 new analysts. This article introduces them and showcases some of their top picks. Top picks include Palantir, Arch Capital Group, and Utah Medical Products, emphasizing an under-recognized growth driver, discounted valuation, and a substantial margin of safety. Analysts also highlighted Sell recommendations on Estée Lauder and Intuitive Surgical, citing deteriorating consumer sentiment and little price upside. seekingalpha.com - 2 weeks ago
2 Stocks I Can't Wait to Buy During the Next Market Correction Investors never know when the next market correction -- a drop of from 10% to 20% in an index -- is coming, but we know that it will eventually happen. And because that's true, it makes sense to make a list of the stocks you'd like to buy if they dip during a correction. fool.com - 2 weeks ago
Stock Market Selloff: 4 No-Brainer Stocks to Buy Right Now In 2025, Wall Street has been rattled with increasing concerns about U.S.-China trade wars, escalating geopolitical pressures, rising economic uncertainties, and growing recession fears. The benchmark S&P 500 index is down nearly 4.7% in 2025. fool.com - 2 weeks ago
Prediction: 2 Stocks Will Be Worth More Than Palantir Technologies in 2026 Palantir Technologies is currently worth $269 billion. But these Wall Street analysts think Intuitive Surgical (ISRG 2.29%) and ServiceNow (NOW 2.00%) can top that figure in 2026: fool.com - 2 weeks ago
Intuitive Announces FDA Clearance of da Vinci Single Port for Transanal Local Excision/Resection SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared the da Vinci Single Port (SP) surgical system for transanal local excision/resection, a form of minimally invasive surgery performed through a natural orifice to avoid abdominal surgical incisions for select procedures. This clearance extends the da Vinci SP's capabilities in colorectal surgery, building upon procedures previously cleared by the FDA in November 2024, which include transabdominal procedures - low anterior resection, total mesorectal excision, colectomy, abdominoperineal resection, and sigmoidectomy. globenewswire.com - 2 weeks ago
Trump's Tariffs Could Impact This Top Growth Stock. Here's Why It's Still a Buy President Donald Trump's macroeconomic policies are creating significant uncertainty. His decision to impose sweeping tariffs on goods imported into the U.S. could harm the economy and specific corporations in ways that are scaring off investors. fool.com - 2 weeks ago
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst. seekingalpha.com - 3 weeks ago
Baron Health Care Fund Q1 2025 Top Contributors And Detractors Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, insulating it from tariff impacts. seekingalpha.com - 3 weeks ago
ISRG vs. SYK: Which Robotic-Device Innovator Is a Better Buy? As robotic-assisted surgery becomes a cornerstone of modern healthcare, two medtech giants — Intuitive Surgical ISRG and Stryker SYK — are leading the charge. Intuitive, the pioneer behind the da Vinci Surgical System, has long dominated soft tissue procedures. zacks.com - 3 weeks ago
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. zacks.com - 3 weeks ago
2 Growth Stocks to Buy on the Dip if the Market Crashes Again Anxious investors who picked April to go on a long internet-free vacation couldn't have planned it better. Earlier this month, the S&P 500 index quickly sank more than 10% after President Donald Trump unveiled tariff rules that threatened the U.S. economy. fool.com - 3 weeks ago
8. Profile Summary

Intuitive Surgical, Inc. ISRG

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 192 B
Dividend Yield 0.00%
Description Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Contact 1020 Kifer Road, Sunnyvale, CA, 94086-5304 https://www.intuitive.com
IPO Date June 16, 2000
Employees 15638
Officers Mr. David J. Rosa President & Director Mr. Fredrik Widman Vice President, Principal Accounting Officer & Corporate Controller Mr. Gary H. Loeb J.D. Executive Vice President and Chief Legal & Compliance Officer Ms. Patricia Wadors Chief Human Resources Officer Mr. Brian King Vice President, Treasurer & Head of Investor Relations Dr. Brian E. Miller Ph.D. Executive Vice President & Chief Digital Officer Dr. Gary S. Guthart Ph.D. Chief Executive Officer & Director Mr. Jamie E. Samath Executive Vice President, Chief Financial Officer and Head of Business Technology Mr. Henry L. Charlton Executive Vice President and Chief Commercial & Marketing Officer Dr. Christopher R. Carlson Ph.D. Executive Vice President of Research, Corporate Development & Intuitive Ventures